Navigation Links
Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases
Date:5/24/2013

23 May 2013, Paris, France: Routinely measuring fractional flow reserve (FFR) using pressure wire assessment during coronary angiography for diagnosis of chest pain leads to significant changes in the management of one in four patients, according to results from a study reported at EuroPCR 2013.

The RIPCORD (Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain) study was designed to assess whether routine assessment of FFR in all the main coronary branches would significantly change the management strategy derived from diagnostic angiography alone.

"Angiographic assessment of chest pain is flawed because it doesn't assess the functional significance of coronary artery disease," said the lead author of the study Nick Curzen, Professor of Interventional Cardiology, University Hospital Southampton NHS Foundation Trust and Faculty of Medicine, University of Southampton, Southampton, UK.

He explained that ischaemia is the most important determinant of clinical outcome in coronary artery disease. FFR provides an accurate and reproducible method for detection of ischaemia by measuring the pressure drop across a lesion and previous studies have shown better clinical outcomes of FFR-guided treatment compared to angiography alone. "But, despite this, most patients with chest pain are assessed by angiogram alone," he told the conference.

RIPCORD recruited 200 patients being investigated for chest pain at 10 UK centres. They all underwent diagnostic coronary angiography carried out by one cardiologist who used the results to develop a treatment plan (plan 1) giving recommendations for medical treatment, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or to request more information.

The first cardiologist then left the room and each patient in the study had FFR measured in all patent vessels of stentable (>2.25mm) diameter by a second cardiologist. The FFR results were shown to the first cardiologist, who used them to develop a second treatment plan (plan 2) for that patient. The primary endpoint of the study was the difference between plan 1 and plan 2 for each patient.

"Routine use of FFR at diagnostic coronary angiography resulted in a significant change in management in 26% of patients," Curzen reported. FFR led to a change in the judgement of whether a coronary artery had a 'significant' lesion in 64 patients (32%) compared to angiogram alone. "These results have potentially important implications for clinical practice," he concluded. "Management of patients with stable angina alone is flawed and would be improved by routine use of FFR at the diagnostic stage." He suggested that RIPCORD has provided proof of principle and that a large-scale randomised trial comparing angiographic- with FFR-guided assessment and management of patients with stable angina undergoing diagnostic angiography is now warranted.

Commenting on the implications of the study findings, Kari Niemela, Medical Director and founder of the Heart Center Co., Tampere University Hospital, Tampere, Finland, said, "The RIPCORD trial demonstrated that routine measurement of FFR in patients with stable angina pectoris changes treatment plan in one out of four patients as compared to visual evaluation with coronary angiography alone." He added, "As the number of patients in this highly interesting multicentre trial was relatively small (200 patients), a large-scale randomised controlled trial including a health economic assessment of both diagnostic options for routine use is justified."


'/>"/>

Contact: Isabelle Uzielli
iuzielli@europcr.com
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com
2. Ariosa Diagnostics Expands Harmony Prenatal Test to Twin Pregnancies and Launches New X,Y Analysis Test
3. Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com
4. MarketResearch.com Announces the Release of New Report Called The World Market for Molecular Diagnostics, 5th Edition
5. A cautionary tale on genome-sequencing diagnostics for rare diseases
6. Expert Panel to Discuss Perspectives on Evaluating Novel Diagnostics for Reimbursement at 2013 Next Generation Dx Summit In Washington, DC
7. Traumatic brain injury poses complex diagnostic, management and treatment challenges in older people
8. Penn Medicines new center for personalized diagnostics unlocks cancers secrets
9. ORNLs awake imaging device moves diagnostics field forward
10. Advanced Mold Diagnostics Receives Angie's List Super Service Award for 4th Straight Year
11. Craig Medical Distribution has Opened its line of Professional Diagnostic Products to the General Public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology: